Trial Profile
A pivotal Phase 3 trial of LB1148 in patients undergoing major cardiovascular surgery
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 23 Mar 2022
Price :
$35
*
At a glance
- Drugs Tranexamic acid (Primary)
- Indications Cardiogenic shock
- Focus Registrational; Therapeutic Use
- Sponsors Leading BioSciences; Palisade Bio
- 18 Mar 2022 According to a Palisade Bio media release, the company anticipates initiating enrollment of the first patients in the phase 3 study in the second half of 2022.
- 08 Nov 2018 New trial record
- 30 Oct 2018 According to a Leading BioSciences media release, the company is planning to initiate the study by the end of 2018.